2019
Economic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current Era
Kadatz M, Gill JS, Gill J, Formica RN, Klarenbach S. Economic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current Era. Journal Of The American Society Of Nephrology 2019, 31: 218-228. PMID: 31704739, PMCID: PMC6934999, DOI: 10.1681/asn.2019070646.Peer-Reviewed Original ResearchConceptsKidney transplant recipientsQuality-adjusted life yearsTransplant recipientsTransplant survivalDrug coverageMedicare coverageTransplant failureImmunosuppressant drugsAdditional quality-adjusted life yearCohort of MedicareMultivariable survival analysisIncremental cost-utility ratioBetter patient outcomesCost-utility ratioImmunosuppressant medicationsTransplant functionImmunosuppressive drugsPatient outcomesMedicare payersSurvival analysisLife yearsIncremental costRecipientsSurvivalDrugs
2014
New National Allocation Policy for Deceased Donor Kidneys in the United States and Possible Effect on Patient Outcomes
Israni AK, Salkowski N, Gustafson S, Snyder JJ, Friedewald JJ, Formica RN, Wang X, Shteyn E, Cherikh W, Stewart D, Samana CJ, Chung A, Hart A, Kasiske BL. New National Allocation Policy for Deceased Donor Kidneys in the United States and Possible Effect on Patient Outcomes. Journal Of The American Society Of Nephrology 2014, 25: 1842-1848. PMID: 24833128, PMCID: PMC4116061, DOI: 10.1681/asn.2013070784.Peer-Reviewed Original ResearchConceptsPost-transplant survivalKidney Donor Profile IndexKidney allocation policyBetter post-transplant survivalOverall post-transplant survivalBlood type A2Panel reactive antibodyDeceased donor kidneysBlood type B candidatesNational allocation policyCurrent allocation policyBlood type BRace/ethnicityA2B kidneysKDPI scoreDialysis initiationDonor kidneysDonor factorsDistribution of kidneysPatient outcomesOrgan procurementTransplantation NetworkKidneyKidney allocationTransplant